Zinc metal anode in aqueous zinc-ion batteries (AZIBs) is considerably impeded by uncontrollable dendrite growth and intricately water-induced corrosion, leading to low Coulombic efficiency (CE) and limited lifespan. Herein, a...

Aqueous zinc‐ion batteries (AZIBs) are promising candidates for large‐scale energy storage due to the high safety and cost effectiveness. Yet it is suffered from the obscurely uncontrolled Zn2+ deposition that accumulates together and easily penetrates the separator. Here, a 3D long‐range ordered polyacrylonitrile (PAN) nanofiber separator is designed to overcome this barrier. The N atoms on the surface of separator uniformly distribute the ion flux and guide the cation transport through available N–Zn bonds. Hence, the electric field on the anode is evenly distributed, which helps to guide the nucleation, growth, and deposition of zinc ions. Benefit from this functional group, a Zn symmetric cell with PAN separator shows a long‐term stability and dendrite‐free deposition layer with a preferred (101) crystallographic orientation. Meanwhile, the Zn/NH4V4O10 cells display high specific capacity and excellent long‐term durability of 89.2% capacity retention after 1500 cycles at 10 A g−1. This work demonstrates the design of functional separator provides an effective way to modify Zn2+ deposition behavior and achieve a dendrite‐free Zn metal anode.

Currently, most thrombolytic agents are limited by short circulation time and excessive dose needed for clinical therapy, which increases lethal risk for intracranial hemorrhage. Here, a near-infrared-triggered, controlledrelease system, using gold@mesoporous silica core-shell nanospheres (Au@MSNs) with phase-changed material 1-tetradecanol, is formulated to release urokinase plasminogen activators (uPA) on demand. The prepared system presents a sensitive system for releasing uPA, owing to an elevated temperature created by Au@MSNs-induced photothermal effect. For in vitro study, a 3D printed vein vasculature is designed and fabricated to simulate the thrombolysis of system in blood vessel. Murine tail thrombus model is also built to evaluate thrombolysis in vivo. Consequently, localized hyperthermia is validated to possess an effective enhancement for thrombolysis. Therefore, according to the results, the fabricated system demonstrates two aspects of potential superiority: controlled uPA release for reducing risk of side effects, and hyperthermia-enhanced thrombolysis locally for decreasing drug dosage. Assisted with thermal thrombolysis, the present formulated system shows a high efficiency, on-demand drug release, and thus a safer protocol for thrombolytic therapy, which fits the developing trends of precision medicine.

Optimized method for synthesis of CsPbI3 NCs using dodecyldimethylammonium bromide as capping molecules can achieve enhanced stability.